All In Biotech

Drug Trial Radar · NCT01313637

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease

Last checked: Nov 19, 2026Latest source record: Jan 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,493 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,493

Actual

Start

Mar 1, 2011

Primary completion

Mar 1, 2012

Study completion Apr 19, 2012

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Mar 14, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation Powder and Placebo when administered once-daily via a Novel Dry Powder Inhaler over a 24-week treatment period in subjects with COPD. Subjects who meet eligibility criteria at Screening (Visit 1) will complete a 7 to14 day run-in period followed by a randomization visit (Visit 2) then a 24-week treatment period. There will be a total of 9 clinic study visits. A follow-up phone contact for adverse event assessment will be conducted approximately one week after the last study visit (Visit 9 or Early Withdrawal). The total duration of subject participation in the study will be approximately 27 weeks. A subset of subjects at selected sites will also perform 24-hour serial spirometry and Holter monitoring during the study and provide serial blood samples for pharmacokinetic analysis. Sparse pharmacokinetic sampling for population pharmacokinetic analyses will be obtained from non-subset subjects. The primary measure of efficacy is clinic visit trough (pre-bronchodilator and pre-dose) FEV1 on Treatment Day 169. Safety will be assessed by adverse events, 12-lead ECGs, vital signs, clinical laboratory tests, and 24 hour Holter monitoring (subset only).

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • GSK573719/GW642444 125/25mcgDrug

    125/25mcg

  • GSK573719 125mcgDrug

    125mcg

  • GW642444 25mcgDrug

    25mcg

  • Placebo onlyDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)Time frame: Baseline and Day 169

Locations

157 sites in 14 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Jasper, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Palo Alto, California

  • GSK Investigational Site

    Riverside, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Torrance, California

  • GSK Investigational Site

    Clearwater, Florida

  • GSK Investigational Site

    DeLand, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Panama City, Florida

  • GSK Investigational Site

    Topeka, Kansas

  • GSK Investigational Site

    Livonia, Michigan

  • GSK Investigational Site

    Plymouth, Minnesota

  • GSK Investigational Site

    Lincoln, Nebraska

  • GSK Investigational Site

    Cherry Hill, New Jersey

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Easley, South Carolina

  • GSK Investigational Site

    Greenville, South Carolina

  • GSK Investigational Site

    Spartanburg, South Carolina

  • GSK Investigational Site

    Union, South Carolina

  • GSK Investigational Site

    Richmond, Virginia

  • GSK Investigational Site

    Aalst, Belgium

  • GSK Investigational Site

    Edegem, Belgium

  • GSK Investigational Site

    Genk, Belgium

  • GSK Investigational Site

    Kortrijk, Belgium

  • GSK Investigational Site

    Liège, Belgium

  • GSK Investigational Site

    Aalborg, Denmark

  • GSK Investigational Site

    Copenhagen, Denmark

  • GSK Investigational Site

    Hvidovre, Denmark

  • GSK Investigational Site

    Næstved, Denmark

  • GSK Investigational Site

    Odense C, Denmark

  • GSK Investigational Site

    Roedovre, Denmark

  • GSK Investigational Site

    Roskilde, Denmark

  • GSK Investigational Site

    Haapsalu, Estonia

  • GSK Investigational Site

    Pärnu, Estonia

  • GSK Investigational Site

    Rakvere, Estonia

  • GSK Investigational Site

    Tallinn, Estonia

Showing 40 of 157 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.